Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT

[1]  H. Zaidi,et al.  PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions , 2021, Frontiers in Oncology.

[2]  A. Kishan,et al.  Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol , 2021, BMC Cancer.

[3]  A. Kishan,et al.  Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol , 2021, BMC cancer.

[4]  F. Alongi,et al.  Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes , 2021, La radiologia medica.

[5]  M. Picchio,et al.  Ga-Labeled Prostate-specific Membrane Antigen Ligand Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis Prostate Cancer: A Systematic Rev , 2021 .

[6]  A. Kishan,et al.  Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. , 2020, European urology focus.

[7]  L. Livi,et al.  Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. , 2020, Clinical genitourinary cancer.

[8]  L. Emmett.  Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer. , 2020, Seminars in oncology nursing.

[9]  P. Giraud,et al.  Prostate imaging: Contribution of PET PSMA and MRI. , 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[10]  E. Goetghebeur,et al.  PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial , 2020, BMC Cancer.

[11]  H. Woo,et al.  Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross‐sectional study of the additive diagnostic value of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for me , 2020 .

[12]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[13]  N. Lawrentschuk,et al.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.

[14]  C. Buchpiguel,et al.  Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings , 2020, Cancer Imaging.

[15]  H. Zacho,et al.  PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review , 2020, Cancer Imaging.

[16]  F. Alongi,et al.  New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming? , 2019, Translational andrology and urology.

[17]  D. Murphy,et al.  The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. , 2019, Current opinion in urology.

[18]  David C. Smith,et al.  Focal radiation for oligometastatic castration-resistant prostate cancer (FORCE): A phase II randomized trial. , 2019, Journal of Clinical Oncology.

[19]  Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis , 2019, Case Medical Research.

[20]  A. Zwinderman,et al.  Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. , 2019, European urology.

[21]  D. Elashoff,et al.  Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] , 2019, BMC Cancer.

[22]  A. Costello,et al.  Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial , 2019, International journal of cancer.

[23]  D. Elashoff,et al.  Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] , 2019, BMC Cancer.

[24]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[25]  N. Lawrentschuk,et al.  Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.

[26]  P. Wust,et al.  PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives , 2018, Radiation oncology.

[27]  P. Erba,et al.  Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer. , 2018, Anticancer research.

[28]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Picchio,et al.  68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology focus.

[30]  Publisher's Note , 2018, Anaesthesia.

[31]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[32]  T. Shakespeare.  Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists , 2015, Radiation oncology.

[33]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.